Overview

FIL Study on ABVD DD-DI as Upfront Therapy in HL.

Status:
Active, not recruiting

Trial end date:
2023-01-01

Target enrollment:

Participant gender:

Summary

The FIL-Rouge is a randomized, open-label, multicenter, phase III, 2-arm study. The primary objective is to compare efficacy and tolerability of the intensified variant 'dose-dense/dose-intense ABVD' (ABVD DD-DI) with an interim PET response-adapted ABVD program as upfront therapy in advanced-stage classical Hodgkin Lymphoma (HL).

Phase:

Phase 3

Details

Lead Sponsor:

Fondazione Italiana Linfomi ONLUS

Treatments:

Bleomycin
Dacarbazine
Doxorubicin
Liposomal doxorubicin
Vinblastine